Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel mRNA-based assay. Existing targeted drugs with tolerable toxicity profiles are used to investigate the therapeutic value beyond their approved indication, which are deemed beneficial in the select group of patients with a relevant predominantly active functional STP, in order to improve survival and maintain quality of life.

Trial Details

NCT ID
NCT03458221
Phase
PHASE2 / PHASE3
Sponsor
Gynaecologisch Oncologisch Centrum Zuid
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Letrozole Oral Product
  • Bicalutamide Oral Product
  • Everolimus Oral Product
  • Itraconazole Oral Product
Locations (sample)
  • Nijmegen, Gelderland, Netherlands|51.8425,5.85278
  • Eindhoven, North Brabant, Netherlands|51.44083,5.47778
  • Breda, Netherlands|51.58656,4.77596
  • Maastricht, Netherlands|50.84833,5.68889
  • Rotterdam, Netherlands|51.9225,4.47917

Key Eligibility Criteria

  • Female, age \> 18 years
  • Patients with recurrent ovarian cancer who meet one of the following criteria:
  • Platinum-resistant disease, defined as disease recurrence or progression within six months of last platinum-based chemotherapy or;
  • Patient refrains from standard therapy or;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →